Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
ArcticZymes Technologies ASA is a Norwegian life science company specializing in the development, manufacturing, and commercialization of novel, high-quality recombinant enzymes. These enzymes, including pioneering salt-active nucleases and cold-adapted marine varieties, serve critical applications in molecular research, in vitro diagnostics, and biomanufacturing for therapeutics, gene therapy, and vaccines. Drawing from over three decades of research at the Arctic University of Tromsø, the company produces GMP-grade products that excel in challenging conditions like high-salt and low-temperature environments, ensuring robust performance and reliability. ArcticZymes Technologies ASA operates from Tromsø, employs around 53 people, and generates significant revenue primarily from the USA, Lithuania, and Europe through its Enzymes segment. Protected by a strong patent portfolio and certified under ISO 13485, the firm emphasizes quality assurance, innovation, and long-term customer partnerships to advance boundaries in biotechnology and healthcare sectors.
NOK 1.74
+NOK 0.01 (+0.58%)
EOD Jul 1, 2026
Operating margin is thin at 2.33%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 7.9%, steady but not accelerating.
Even for strong businesses, today's 7x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
6.7x earnings, 4.4x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 121M
▲ +7.9% YoY
Net Income (TTM)
NOK 14M
▲ +15.0% YoY
Op. Margin
6.65%
▲ +3.7pp YoY
ROIC
0.63%
▲ +1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
NOK 23M
▲ +381.8% YoY
Op. Cash Flow (TTM)
NOK 23M
▲ +5594.4% YoY
Net Debt
-NOK 258M
Net Cash Position
Cash & Equiv.
NOK 263M
3Y CAGR: -6.3%
3Y CAGR: -21.6%
Continue Research
At a P/E of 6.7 and a price-to-free-cash-flow of 4.4, ArcticZymes Technologies ASA (AZT.XOSL) trades below a two-stage DCF intrinsic value of about NOK 11.25 per share, so at NOK 1.74 the stock looks undervalued (546.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, ArcticZymes Technologies ASA scores 35/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about NOK 11.25 per share for AZT.XOSL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around NOK 8.43. At today's NOK 1.74, that puts the stock about 546.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
ArcticZymes Technologies ASA scores 35 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 6.7% operating margin and a 0.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. AZT.XOSL currently trades below its estimated intrinsic value and scores 35/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.